Varda Space Industries said it has signed up United Therapeutics for a commercial program to produce drug materials in microgravity. The plan is to launch versions of United’s drugs into orbit so they can form crystals under conditions not available on Earth, potentially yielding improved stability characteristics. If successful, the partnership would represent a practical commercialization path for space-based pharmaceutical manufacturing beyond government-backed experiments. It also reflects a growing push to extend patent life and formulation differentiation by engineering physical properties. For biotech operations, the deal is notable as a manufacturing strategy—linking R&D, physical characterization, and lifecycle management to a new production environment.